Drug Approval | March 28, 2024
Biocon to obtain approval for diabetes drug, Liraglutide in UK
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
WINREVAIR is a breakthrough biologic for this rare, progressive disease
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Vision loss due to Glaucoma can be prevented if it is detected and treated early
The WHO GMP approved vertically integrated ONCOLOGY unit of SAKAR has been selling products nationally since few quarters
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
The company intends to respond to the two minor observations within the stipulated time
The company has received five final approvals
Subscribe To Our Newsletter & Stay Updated
